Hofseth BioCare ASA

hofsethbiocare.no

Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. Hofseth BioCare's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SARTORIUS STEDIM BIOTECH CLOSES ACQUISITION OF SLOVENIAN PURIFICATION SPECIALIST BIA SEPARATIONS

Sartorius | November 03, 2020

news image

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees,&...

Read More

AXON NEUROSCIENCE, A CLINICAL-STAGE BIOTECH COMPANY TO LAUNCH WORLD'S FIRST CROWDFUNDED VACCINE AGAINST COVID-19

COVIDAX | September 19, 2020

news image

AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1. With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine agains...

Read More

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More

INDUSTRIAL IMPACT

SHOUTI INTRODUCES BASECAMP BIO AS A WHOLLY OWNED SUBSIDIARY TO EXPAND PIPELINE AND PARTNERSHIPS

ShouTi Inc | February 18, 2022

news image

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecut...

Read More
news image

SARTORIUS STEDIM BIOTECH CLOSES ACQUISITION OF SLOVENIAN PURIFICATION SPECIALIST BIA SEPARATIONS

Sartorius | November 03, 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees,&...

Read More
news image

AXON NEUROSCIENCE, A CLINICAL-STAGE BIOTECH COMPANY TO LAUNCH WORLD'S FIRST CROWDFUNDED VACCINE AGAINST COVID-19

COVIDAX | September 19, 2020

AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1. With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine agains...

Read More
news image

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More
news image

INDUSTRIAL IMPACT

SHOUTI INTRODUCES BASECAMP BIO AS A WHOLLY OWNED SUBSIDIARY TO EXPAND PIPELINE AND PARTNERSHIPS

ShouTi Inc | February 18, 2022

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecut...

Read More